Public Release: 

New robot AntiAgeist joins jury of Beauty.AI 2.0

Insilico Medicine enrolls a new algorithm as a jury of robots to evaluating perception of human age into Beauty.AI

InSilico Medicine, Inc.

IMAGE

IMAGE: Beauty.AI logo. view more

Credit: Beauty.AI

  • Insilico Medicine developed an algorithm called AntiAgeist, which compares actual human age with "perceived" human age predicted by deep neural networks
  • The algorithm is part of Insilico Medicine's effort to build a comprehensive and actionable deep-learned biomarker of human aging and general health status recently published and available at Aging.AI
  • Beauty.AI 2.0 is the second beauty competition, where humans are evaluated by a panel of robot judges with prizes for human participants and for innovative algorithms

June 27, Baltimore, MD - Youth Laboratories, the organizer of the first beauty contest judged by a panel of robots today announced the inclusion of AntiAgeist, an algorithm evaluating the difference between the chronological age of contest participants and the age predicted by a system of deep neural networks trained to predict human age.

"We are very happy to have AntiAgeist on our jury of robot judges, since this is a rather novel idea of looking at beauty through the prism of how successfully the person is aging. We encourage teams from all over the world to submit algorithms and ideas on how machines can evaluate human beauty to the Beauty.AI contest. Best algorithms will get monetary prizes and will be promoted worldwide", said Anastasia Georgievskaya, general manager of Beauty.AI.

Insilico Medicine specializes in drug discovery and biomarker development for a broad range of diseases with a mission to accelerate and improve lead generation and pre-clinical studies within biotechnology and pharmaceutical industries. One of the core missions of Insilico Medicine is extending productive longevity and the company engages in a broad range of basic and applied research projects focused on human aging.

"While our business focus in on applying deep learning to drug discovery and lead generation, from its very inception Insilico Medicine is committed to aging research and it is only natural for us to combine blood and tissue-specific transcriptomic, metabolomic and blood biochemistry markers with imaging. Inspired by Microsoft's How-Old.net, AntiAgeist is a result of these experiments and we are happy to pass it over to Youth Laboratories for the Beauty.AI contest", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.

Earlier this month Insilico Medicine signed an exclusive agreement with Life Extension, a major nutraceutical product vendor to collaboratively develop set of geroprotectors, natural products that mimic the healthy young state in multiple old tissues. This products are able to increase rejuvenation rate of the human body and slow down or even reverse aging process.

Recently Insilico Medicine published several key papers on applying deep learning techniques to biomedical applications in influential peer-reviewed journals including "Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data" in Molecular Pharmaceutics. The paper received the Editors' Choice Award from the American Chemical Society. "Applications of Deep Learning in Biomedicine" in also in Molecular Pharmaceutics and "Deep biomarkers of human aging: Application of deep neural networks to biomarker development" in Aging, one of the highest-impact journals in aging research.

Beauty.AI is a platform where both humans and algorithms compete for prizes to explore new ideas and strategies that may be used to impartially evaluate human beauty. Beauty.AI 2.0 contest started in May will conclude in August 2016. Humans are welcome to download the Beauty.AI mobile app and submit series of pictures to this competition before 19th of July.

The contest is sponsored by multilpe cosmetics and IT companies supported the contest including Nvidia, Ernst & Young, Microsoft, Imagene Labs, Faberlique, Klinikk Oslo, Asia Genomics, Insilico Medicine, and many others.

###

About Insilico Medicine

Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore with R&D resources in Belgium, Russia and Poland hiring talent through hackathons and competitions. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery. Through its Pharma.AI division the company provides advanced machine learning services to biotechnology, pharmaceutical and skin care companies. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

About Youth Laboratories

Youth Laboratories is a company dedicated to helping people retain youthful state for as long as possible using advances in machine vision and artificial intelligence. The company is run by a team of computer and data scientists, biologists, biogerontologists and business people on a quest to develop novel biomarkers and anti-aging interventions. The company develops series of mobile applications that track age-related changes, wrinkles, pimples, dark spots and other parameters affecting perception of beauty, health and youthfulness and help evaluate the effectiveness of multiple interventions. The company's first application is called RYNKL, developed using the funds crowd sourced via Kickstarter. Youth Laboratories helped to launch the first beauty contest to be judged by artificial intelligence for both humans and algorithms http://www.Beauty.AI.

Beauty.AI in GooglePlay: https://play.google.com/store/apps/details?id=com.beauty_ai

Beauty.AI in App Store: https://itunes.apple.com/ru/app/beauty.ai/id1060865109?mt=8

RYNKL website: http://rynkl.com

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.